Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AbundRX vs Wisp

AbundRX
Graded #181

Higher grade

vs+2.1999999999999886
Wisp
Graded #243

Lower grade

The verdict

AbundRX takes it — 66.6/100 to 64.4/100.

AbundRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. AbundRX (Abundant Wellness) is an online medical weight-care platform connecting patients with licensed clinicians for compounded GLP-1 treatment.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAbundRX +17
67
50
Dose & formulationWisp +12
64
76
Clinical oversightWisp +3
79
82
Labs & monitoringEven
53
53
FulfillmentAbundRX +8
74
66
Contract termsEven
55
55
AbundRX · left barWisp · right bar

The numbers

MetricAbundRXWisp
WeighScore66.6/10064.4/100
GradeCC
Scorecard rank#181#243
Semaglutide$179/mo (compounded)$225/mo (compounded oral)
Tirzepatide$279/mo (compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
AbundRX

Graded #181 · C

Strengths

  • Two clear compounded GLP-1 pathways with transparent pricing — semaglutide $179/mo and tirzepatide $279/mo
  • Fast, free shipping and a simple few-minute online health assessment
  • Provider-guided care connecting patients with licensed US clinicians
  • Publishes Terms, Privacy, and Refund policies

Where it loses points

  • Claims LegitScript certification in text but displays no verifiable seal or listing
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Compounding pharmacy not named; no HIPAA notice found; state availability not published
  • Heavily hedged marketing language ('may include', 'helping connect patients') — reads like a lead-generation platform
Wisp

Graded #243 · C

Strengths

  • Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
  • LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
  • Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary

Where it loses points

  • The $99/mo tirzepatide figure is a consultation-and-care subscription, not the medication: Zepbound is filled at a pharmacy of your choice at its own cost, which Wisp does not publish
  • The compounded semaglutide option is sublingual drops, which Wisp itself describes as less effective than injection
  • Brand-name access is a prescription, not a dispensed product, so the drug cost is outside anything quoted here

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard